Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/26/23	€1.140	0.00%	0
22/26/22	€1.140	-0.87%	25,000
21/26/21	€1.150	-0.86%	2,000
20/26/20	€1.160	-1.69%	9,000
17/26/17	€1.180	-1.67%	9,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana Other stock markets 09:15:00 23/07/2026 pm IST			5-day change	1st Jan Change
1.140 ^EUR	0.00%		-5.00%	-22.45%

06/07	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
29/06	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN

Market Cap	97.13L 1.1Cr 90.23L 82.99L 1.56Cr 106.95Cr 1.58Cr 11Cr 4.21Cr 52Cr 4.15Cr 4.06Cr 180.97Cr	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	1Cr 1.14Cr 92.98L 85.51L 1.6Cr 110.2Cr 1.63Cr 11Cr 4.34Cr 54Cr 4.27Cr 4.18Cr 186.48Cr	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

06/07	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
29/06	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
22/06	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
20/06	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
15/06	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
04/06	Equities trend higher; banks lead gains on the MIB	AN
22/05	European markets rebound; STM and Stellantis lead gains	AN
21/05	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
21/05	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
21/05	European markets set for lower open; focus on manufacturing PMIs	AN
20/04	Brent rebounds; futures signal risk-off sentiment	AN
17/04	Greenlight on Hormuz sparks global equity rally	AN
13/04	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

09/04	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/25/21	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/25/29	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/25/04	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/25/19	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Share Price

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06/07	Laboratorio Erfo prosegue buyback e rileva 15.000 azioni proprie
29/06	Laboratorio Farmaceutico Erfo rileva 14.000 azioni proprie
22/06	Erfo prosegue coi buyback e riacquista 28.000 azioni
15/06	Laboratorio Farmaceutico Erfo acquista 15.000 azioni proprie
04/06	Borse rialziste; bene i bancari sul MIB

1 week	-5.00%
Current month	-3.39%
3 months	-9.52%
6 months	-18.28%
Current year	-22.45%

1 week	1.1	1.18
1 month	1.1	1.26
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	01/01/2013
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	01/01/2013
Flavio Corpina BRD	Director/Board Member	47	01/01/2017
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	9,68,000	10.7556%
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	3,22,000	3.5778%
29/06/22	Alessandro Cutè	Others	Chief Executive Officer	3,00,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	0.00%	-5.00%	-11.28%	+16.33%	1.11Cr
ELI LILLY AND COMPANY	+1.68%	+1.47%	+48.50%	+158.29%	1,03700Cr
JOHNSON & JOHNSON	+1.07%	+3.43%	+52.90%	+51.13%	62TCr
ABBVIE INC.	+0.99%	+0.57%	+34.26%	+78.68%	45TCr
ROCHE HOLDING AG	+5.14%	+5.40%	+33.75%	+27.79%	33TCr
NOVARTIS AG	+1.85%	+3.57%	+37.09%	+40.59%	29TCr
ASTRAZENECA PLC	-0.11%	+0.48%	+18.87%	+17.70%	26TCr
NOVO NORDISK A/S	+0.25%	-4.62%	-27.66%	-41.76%	22TCr
AMGEN INC.	+0.64%	-0.94%	+19.04%	+56.36%	20TCr
GILEAD SCIENCES, INC.	-0.18%	-4.66%	+14.43%	+67.33%	16TCr
Average	+1.11%	+0.43%	+21.99%	+47.24%	35.57TCr
Weighted average by Cap.	+1.44%	+1.47%	+35.18%	+75.75%

	2024	2025
Net sales	60.32L 68.59L 56.04L 51.54L 96.66L 66Cr 98.39L 6.7Cr 2.61Cr 32Cr 2.57Cr 2.52Cr 112.4Cr	97.32L 1.11Cr 90.41L 83.15L 1.56Cr 107.16Cr 1.59Cr 11Cr 4.22Cr 52Cr 4.15Cr 4.06Cr 181.33Cr
Net income	4L 4L 3L 3L 6L 3.88Cr 6L 39.19L 15.29L 1.89Cr 15.06L 14.73L 6.57Cr	7L 8L 7L 6L 11.81L 8.11Cr 12.02L 81.87L 31.93L 3.96Cr 31.46L 30.78L 14Cr
Net Debt	5.77T 6.56T 5.36T 4.93T 9.24T 6L 9.41T 64.07T 24.99T 3L 24.62T 24.08T 10.75L	3L 3L 3L 3L 5L 3.25Cr 5L 32.82L 12.8L 1.59Cr 12.61L 12.34L 5.5Cr